Physician profile
Monica E Ray
NPI 1497277578
$2,715.61
in general payments reported to CMS, 2019-2025
19 companies · $64.01 in 2025
The $64.01 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,126 · 2022: $1,184 · 2023: $263 · 2024: $78.50 · 2025: $64.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $881.20 | 2021-2022 | |
| Csl Behring | $357.88 | 2021-2023 | Hizentra |
| Pfizer INC. | $292.79 | 2021-2022 | |
| Glaxosmithkline, LLC. | $264.74 | 2021-2023 | Trelegy Ellipta |
| Octapharma USA, INC. | $201.64 | 2022-2025 | Cutaquig, Panzyga |
| Kaleo, INC. | $108.09 | 2021-2023 | Auvi-Q |
| Optinose US, INC. | $105.23 | 2021-2023 | |
| Genzyme Corporation | $101.03 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $97.62 | 2021-2022 | |
| Alk-Abello, INC | $59.05 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.24 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $51.00 | 2022-2023 | Airduo Digihaler |
| Genentech USA, INC. | $45.49 | 2023 | Xolair |
| Amgen INC. | $21.88 | 2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $17.90 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.96 | 2021 | |
| Grifols USA, LLC | $15.03 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.91 | 2021 | |
| Leo Pharma INC. | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.